Applicability of second-generation upcyte® human hepatocytes for use in CYP inhibition and induction studies

Pharmacology Research and Perspectives

Volumn 3, Issue 5, 2015, Pages

  Ramachandran, Sarada D ^a   Vivarès, Aurélie ^b   Klieber, Sylvie ^b   Hewitt, Nicola J ^c   Muenst, Bernhard ^a   Heinz, Stefan ^a   Walles, Heike ^d   Braspenning, Joris ^a  

^a Medicyte GmbH   (Germany)

^b SANOFI   (France)

^c SWS   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

CYP induction; CYP inhibition; human; upcyte hepatocytes

Indexed keywords

1 AMINOBENZOTRIAZOLE; AMFEBUTAMONE; CARBAMAZEPINE; CHLORPROPAMIDE; CORTODOXONE; CYTOCHROME P450; CYTOCHROME P450 1A2 INDUCER; CYTOCHROME P450 2B6 INDUCER; CYTOCHROME P450 2C9 INDUCER; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A4; DEXAMETHASONE; FLUMAZENIL; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PENICILLIN DERIVATIVE; PHENOBARBITAL; PHENYTOIN; PIOGLITAZONE; QUINIDINE; RIFAMPICIN; TESTOSTERONE; TOLBUTAMIDE; TROGLITAZONE;

ARTICLE; CELL CULTURE; CULTURE OPTIMIZATION; CURVE FITTING; CYTOTOXICITY; DOSE RESPONSE; ENZYME INHIBITION ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC50; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER CELL; LIVER MICROSOME; MATHEMATICAL MODEL; MTS ASSAY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN INDUCTION; PROTEINASE INHIBITION;

EID: 85020977938     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.161     Document Type: Article

References (31)

1. Antherieu S, Chesne C, Li R, Camus S, Lahoz A, Picazo L, et al. (2010). Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 38: 516–525.
2. Burkard A, Dahn C, Heinz S, Zutavern A, Sonntag-Buck V, Maltman D, et al. (2012). Generation of proliferating human hepatocytes using Upcyte(R) technology: characterisation and applications in induction and cytotoxicity assays. Xenobiotica 42: 939–956.
3. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, et al. (2009). In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos 37: 1339–1354.
4. Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi YA, et al. (2012). Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem 57: 441–448.
5. EMA (2012). Guideline on the investigation of drug interactions. 21 June 2012, CPMP/EWP/560/95/Rev. 1 Corr. 2, Committee for Human Medicinal Products (CHMP) http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
6. Emoto C, Murase S, Sawada Y, Iwasaki K (2005). In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab Pharmacokinet 20: 351–357.
7. Fahmi OA, Boldt S, Kish M, Obach RS, Tremaine LM (2008). Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 36: 1971–1974.
8. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, et al. (2004). Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 32: 348–358.
9. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, et al. (2007). Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320: 72–80.
10. FDA (2012). Guidance for industry: drug interaction studies — study design, data analysis, implications for dosing, and labeling recommendations (Research CfDEa ed). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf
11. Georgoff I, Secott T, Isom HC (1984). Effect of simian virus 40 infection on albumin production by hepatocytes cultured in chemically defined medium and plated on collagen and non-collagen attachment surfaces. J Biol Chem 259: 9595–9602.
12. Hariparsad N, Carr BA, Evers R, Chu X (2008). Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36: 1046–1055.
13. Hewitt NJ, Lecluyse EL, Ferguson SS (2007). Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37: 1196–1224.
14. Kanebratt KP, Andersson TB (2008). HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36: 137–145.
15. LeCluyse EL (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13: 343–368.
16. Levy G, Bomze D, Heinz S, Ramachandran SD, Noerenberg A, Shibolet O, et al. (2015). Genetic induction of metabolically functional, polarized cultures of proliferating human hepatocytes. Nat Biotechnol in press.
17. Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD (2012). Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 40: 706–716.
18. Moeller T, Worzella T, Sobol M, Ma D, Cali JJ, Larson B (2013). Comparison of inhibition of CYP1A2, 2C9 and 3A4 using human liver microsomes and hepatocytes. ISSX, Toronto.
19. Mostafavi SA, Tavakoli N (2004). Relative bioavailability of omeprazole capsules after oral dosing. DARU J Pharm Sci 12: 146–150.
20. Nörenberg A, Heinz S, Scheller K, Hewitt NJ, Braspenning J, Ott M (2013). Optimization of upcyte(R) human hepatocytes for the in vitro micronucleus assay. Mutat Res 758: 69–79.
21. Raucy JL (2003). Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31: 533–539.
22. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, et al. (2004). Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308: 189–197.
23. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, et al. (2006). Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34: 1742–1748.
24. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, et al. (2003). Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31: 439–446.
25. Scheller K, Dally I, Hartmann N, Munst B, Braspenning J, Walles H (2013). Upcyte(R) microvascular endothelial cells repopulate decellularized scaffold. Tissue Eng Part C Methods 19: 57–67.
26. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O (2004). Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 32: 626–631.
27. Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E (2004). Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 279: 29295–29301.
28. Westerink WM, Schoonen WG (2007). Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21: 1581–1591.
29. Youdim KA, Tyman CA, Jones BC, Hyland R (2007). Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay. Drug Metab Dispos 35: 275–282.
30. Yu A, Haining RL (2001). Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29: 1514–1520.
31. Zhou SF, Xue CC, Yu XQ, Li C, Wang G (2007). Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29: 687–710.